INT38990

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1985
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 5.04
Pain Relevance 1.33

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell morphogenesis (IDUA) carbohydrate metabolic process (IDUA) lysosome (IDUA)
Anatomy Link Frequency
fibroblasts 2
central nervous system 2
IDUA (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 25 99.68 Very High Very High Very High
cva 11 97.56 Very High Very High Very High
anesthesia 4 97.20 Very High Very High Very High
intrathecal 35 95.76 Very High Very High Very High
lidocaine 4 88.40 High High
cINOD 5 83.08 Quite High
Inflammation 21 76.64 Quite High
aspirin 4 65.48 Quite High
Spinal cord 5 60.48 Quite High
tolerance 10 49.64 Quite Low
Disease Link Frequency Relevance Heat
Iron-deficiency Anemia 95 100.00 Very High Very High Very High
Chronic Disease 9 99.80 Very High Very High Very High
Mucopolysaccharidoses 28 99.62 Very High Very High Very High
Inflammatory Bowel Disease 24 99.32 Very High Very High Very High
Anaemia 41 99.18 Very High Very High Very High
Congenital Anomalies 14 98.72 Very High Very High Very High
Cv General 3 Under Development 1 97.56 Very High Very High Very High
Disease 69 97.40 Very High Very High Very High
Fistula 1 95.60 Very High Very High Very High
Pancreatitis 1 92.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Mucopolysaccharidosis type I (MPS I) results from a deficiency in the enzyme alpha-L-iduronidase (IDUA), and is characterized by skeletal abnormalities, hepatosplenomegaly and neurological dysfunction.
Negative_regulation (deficiency) of IDUA associated with anesthesia, congenital anomalies and mucopolysaccharidoses
1) Confidence 0.59 Published 2002 Journal Eur. J. Biochem. Section Abstract Doc Link 12047386 Disease Relevance 0.27 Pain Relevance 0.10
Mucopolysaccharidosis type I (MPS I) results from a deficiency in the enzyme alpha-L-iduronidase (IDUA), and is characterized by skeletal abnormalities, hepatosplenomegaly and neurological dysfunction.
Negative_regulation (deficiency) of alpha-L-iduronidase associated with anesthesia, congenital anomalies and mucopolysaccharidoses
2) Confidence 0.59 Published 2002 Journal Eur. J. Biochem. Section Abstract Doc Link 12047386 Disease Relevance 0.27 Pain Relevance 0.10
Mucopolysaccharidosis type I (MPS I), a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA), is characterized by skeletal abnormalities, hepatosplenomegaly and neurological dysfunction.
Negative_regulation (deficiency) of alpha-L-iduronidase associated with anesthesia, congenital anomalies and mucopolysaccharidoses
3) Confidence 0.59 Published 1999 Journal Hum. Gene Ther. Section Abstract Doc Link 10498248 Disease Relevance 0.36 Pain Relevance 0.10
Mucopolysaccharidosis type I (MPS I), a deficiency in the lysosomal enzyme alpha-L-iduronidase (IDUA), is characterized by skeletal abnormalities, hepatosplenomegaly and neurological dysfunction.
Negative_regulation (deficiency) of IDUA associated with anesthesia, congenital anomalies and mucopolysaccharidoses
4) Confidence 0.59 Published 1999 Journal Hum. Gene Ther. Section Abstract Doc Link 10498248 Disease Relevance 0.36 Pain Relevance 0.10
It was shown that IDUA was well tolerated, and reduced urinary GAG.
Negative_regulation (reduced) of IDUA
5) Confidence 0.49 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0.18 Pain Relevance 0
Two murine models with genetically engineered IDUA deficiency, as well as feline and canine MPS I models, exist.
Negative_regulation (deficiency) of IDUA
6) Confidence 0.49 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0.32 Pain Relevance 0.08
ERT has become a mainstay of therapy for patients with Hurler-Scheie and Scheie, the attenuated forms of IDUA deficiency that do not have central nervous system manifestations of their disease.
Negative_regulation (deficiency) of IDUA in central nervous system associated with central nervous system and disease
7) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0.37 Pain Relevance 0.05
Based on these limitations, plus the high cost of ERT, the need for weekly infusions over a lifetime, and the possibility of immune-based reactions that may complicate therapy, the critical question is: should cellular therapy be used alone or integrated as multimodal therapy with ERT to best provide optimal correction of IDUA deficiency?


Negative_regulation (deficiency) of IDUA
8) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0 Pain Relevance 0
This would of course pose difficulties for the life-long treatment of IDUA deficiency in the central nervous system.
Negative_regulation (deficiency) of IDUA in central nervous system associated with central nervous system
9) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727896 Disease Relevance 0.19 Pain Relevance 0.38
Anemia in IBD patients is often secondary to a combination of IDA and ACD.
Negative_regulation (combination) of IDA associated with inflammatory bowel disease, anaemia, iron-deficiency anemia and chronic disease
10) Confidence 0.25 Published 2010 Journal Dig Dis Sci Section Body Doc Link PMC2822907 Disease Relevance 2.71 Pain Relevance 0.23
We have studied insulin degrading activity (IDA) in cultured human fibroblasts and assessed the effect of various inhibitors of insulin processing on IDA.
Negative_regulation (inhibitors) of IDA in fibroblasts
11) Confidence 0.22 Published 1985 Journal Endocrinology Section Abstract Doc Link 3882399 Disease Relevance 0 Pain Relevance 0.05
IDA in intact fibroblasts was completely inhibited by 1 mM N-ethylmaleimide and partially by 0.5 mM dansylcadaverine (75%), 0.5 mM chloroquine (48%), 1 mg/ml bacitracin (32%) and Trasylol (30%).
Negative_regulation (inhibited) of IDA in fibroblasts
12) Confidence 0.22 Published 1985 Journal Endocrinology Section Abstract Doc Link 3882399 Disease Relevance 0 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox